Using a "one-drug-fits-all" approach is not going to be a successful paradigm in a complex disease like glioblastoma.
Andrew S. Chi, MD, PhD
Advertisement
Articles by Andrew S. Chi, MD, PhD
Advertisement
Latest Updated Articles
NYU Scientist Sees Hope Peeking Through Gloom of GlioblastomaOctober 4th 2016
Advertisement
Advertisement
Trending on OncLive
1
Vopimetostat Plus Daraxonrasib Yields 92% ORR in MTAP-Deleted, RAS-Mutant Pancreatic Cancer
2
KEYNOTE-D46 Trial Is Discontinued With Sacituzumab Govitecan Plus Pembrolizumab in PD-L1–High NSCLC
3
GU Cancer Experts Highlight the Most Impactful and Discussion-Worthy Data Presented at ASCO 2026
4
May’s GI Monthly Rewind: A Landmark Approval in CCA, Expanded Access for Daraxonrasib, and More Key Pipeline Updates
5